BVES

Across TCGA cell cohorts, BVES mutation is significantly associated with the drug of many other genes, with 9 significant associations in total. LARGE_INTESTINE shows the largest number of these associations.

The most reproducible BVES-associated genes across cancer lineages are 123829, KRAS (G12C) Inhibitor-12, and GSK2606414. Each is linked with BVES in more than 1 cancer types. Because this analysis shows association rather than direction, both BVES-to-partner and partner-to-BVES results are reported.

Each partner links to its own Q-omics profile. The box plot shows the strongest example, 123829 grouped by BVES-low versus BVES-high in LARGE_INTESTINE.

mutation associated genes by consensus

Ranked by combined sampling and lineage consensus. X-score (BVES→partner) and Y-score (partner→BVES) are standardized regression coefficients; both directions are reported because the association is undirected. p-values are from the association test.

Lineage	Partner gene	X-score	Y-score	p(X)	p(Y)	Sampling consensus	Lineage consensus
LARGE_INTESTINE	123829 →	+0.659	+2.649	.023	.046	3	1
LARGE_INTESTINE	KRAS (G12C) Inhibitor-12 →	+0.745	+2.646	.002	.047	3	1
LARGE_INTESTINE	GSK2606414 →	+0.505	+2.769	.008	.040	1	1
LARGE_INTESTINE	Entospletinib →	+0.570	+2.646	.002	.047	1	1
LARGE_INTESTINE	AZD5991 →	+0.959	+2.649	.011	.046	1	1
LARGE_INTESTINE	GSK2256098C →	+0.406	+2.906	.007	.033	1	1

Each partner links to its Q-omics profile. Showing the 6 strongest of 9 associations by consensus.

123829 by BVES expression — LARGE_INTESTINE

Explore this box plot interactively →